Highlights
– In 439 patients ≥60 years without adverse‑risk cytogenetics enrolled to NCRI AML18, DAGO2 produced higher post‑course‑1 CR/CRi and MRD‑negative CR rates than CPX‑351.
– Three‑year event‑free survival (EFS) and overall survival (OS) favored DAGO2: 3‑yr EFS 34% vs 27% (HR 0.73, p=0.012) and 3‑yr OS 52% vs 35% (HR 0.62, p=0.001).
